文献速递神经介入DSA

水凝胶弹簧圈与裸铂弹簧圈在大型或复发动脉瘤(血管内治疗后易复发)患者中的随机对照试验

Hydrogel versus Bare Platinum Coils in Patients with Large or Recurrent Aneurysms Prone to Recurrence after Endovascular Treatment: A Randomized Controlled Trial.
PubMed 文献 · AJNR Am J Neuroradiol · 2017-01-12

PRET为研究者主导的实用型多中心平行随机对照试验,将大型动脉瘤(PRET-1)与复发动脉瘤(PRET-2)患者按1:1分配至水凝胶弹簧圈或裸铂弹簧圈组,主要终点为18个月随访期间残余/复发动脉瘤(盲法核心实验室判定)或再治疗、颅内出血、占位效应的复合终点。因入组缓慢提前终止,PRET-1与PRET-2中两组主要终点及不良事件、病变率均无显著差异,水凝胶弹簧圈未显示优于裸铂弹簧圈。

要点

  • 大型或复发动脉瘤弹簧圈栓塞安全,但造影结果常提示疗效不佳。
  • 水凝胶弹簧圈在PRET-1与PRET-2中均未显示优于裸铂弹簧圈。
  • 两组不良事件与病变率相似,死亡比例水凝胶组高于铂组。

核心结论

  • 大型与复发动脉瘤弹簧圈栓塞安全但造影结果常显示疗效不佳,水凝胶弹簧圈未显示优于裸铂弹簧圈。

研究设计与样本

  • PRET为研究者主导的实用型多中心平行随机(1:1)试验,PRET-1与PRET-2分别随机分配,采用网络平台隐藏分配。
  • 主要终点为盲法核心实验室判定的残余/复发动脉瘤或再治疗、颅内出血、占位效应的复合终点,随访18个月。
  • 因入组缓慢,PRET-1入组250例、PRET-2入组197例后试验提前终止。
  • 原假设水凝胶将18个月主要终点从50%降至30%,每组需125例(PRET-1与PRET-2共500例)。

诊断标准与关键数值

  • PRET-1中铂组主要终点不良结局44.4%(95%CI 35.5%-53.2%),水凝胶组52.5%(95%CI 43.4%-61.6%),OR 1.387(95%CI 0.838-2.295),P=.20。
  • PRET-2中铂组主要终点不良结局49.0%(95%CI 38.8%-59.1%),水凝胶组42.1%(95%CI 32.0%-52.2%),OR 0.959(95%CI 0.428-1.342),P=.34。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 因入组缓慢,PRET-1入组250例、PRET-2入组197例后试验提前终止,未达到原计划每组125例、PRET-1与PRET-2共500例的样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Some patients are at high risk of aneurysm recurrence after endovascular treatment: patients with large aneurysms (Patients Prone to Recurrence After Endovascular Treatment PRET-1) or with aneurysms that have previously recurred after coiling (PRET-2). We aimed to establish whether the use of hydrogel coils improved efficacy outcomes compared with bare platinum coils.

MATERIALS AND METHODS: PRET was an investigator-led, pragmatic, multicenter, parallel, randomized (1:1) trial. Randomized allocation was performed separately for patients in PRET-1 and PRET-2, by using a Web-based platform ensuring concealed allocation. The primary outcome was a composite of a residual/recurrent aneurysm, adjudicated by a blinded core laboratory, or retreatment, intracranial bleeding, or mass effect during the 18-month follow-up. Secondary outcomes included adverse events, mortality, and morbidity (mRS > 2). The hypothesis was that hydrogel would decrease the primary outcome from 50% to 30% at 18 months, necessitating 125 patients per group (500 for PRET-1 and PRET-2).

RESULTS: The trial was stopped once 250 patients in PRET-1 and 197 in PRET-2 had been recruited because of slow accrual. A poor primary outcome occurred in 44.4% (95% CI, 35.5%-53.2%) of those in PRET-1 allocated to platinum compared with 52.5% (95% CI, 43.4%-61.6%) of patients allocated to hydrogel (OR, 1.387; 95% CI, 0.838-2.295; P = .20) and in 49.0% (95% CI, 38.8%-59.1%) in PRET-2 allocated to platinum compared with 42.1% (95% CI, 32.0%-52.2%) allocated to hydrogel (OR, 0.959; 95% CI, 0.428-1.342; P = .34). Adverse events and morbidity were similar. There were 3.6% deaths (1.4% platinum, 5.9% hydrogel; P = .011).

CONCLUSIONS: Coiling of large and recurrent aneurysms is safe but often poorly effective according to angiographic results. Hydrogel coiling was not shown to be better than platinum.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Raymond J, Klink R, Chagnon M, et al. Hydrogel versus Bare Platinum Coils in Patients with Large or Recurrent Aneurysms Prone to Recurrence after Endovascular Treatment: A Randomized Controlled Trial. AJNR Am J Neuroradiol. 2017. PMID: 28082261. doi:10.3174/ajnr.A5101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。